| Prev Close | 134.82 |
| Open | 135.11 |
| Day Low/High | 134.07 / 136.34 |
| 52 Wk Low/High | 121.00 / 148.99 |
| Volume | 7.45M |
| Avg Volume | 7.71M |
Johnson & Johnson (JNJ)
135.95
1.10
0.84
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.63B |
| Market Cap | 354.86B |
| EPS | 5.70 |
| P/E Ratio | 25.70 |
| Div & Yield | 3.80 (2.74%) |
Latest News
Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon
Most important is that the Fed felt the need earlier this week to expand it's minimum offering for overnight repo operations, while also increasing the 14 day repos.
Is the Worst Over for Johnson & Johnson?
A lot of investing is just waiting until the market hates good companies.
Jim Cramer: The Soundness of My Methods
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
Earnings Season Round 2 Starts Today
The majority of the S&P 500 stocks will report in the next two weeks. Focus on individual stock picking, but keep stops tight.
Energy Stocks Are Getting Hammered
There are myriad concerns across the energy complex, the most prevalent one centered around declining global growth reducing the demand for energy.
China Trade, Next Brexit Vote, Fed Action, Trading Lockheed: Market Recon
The Trump and Xi administrations are at least looking at the same page. That's more than nothing.
3 Earnings Reports Will Be Key for the Market Next Week
There is a good foundation for more positive action in the week ahead.
Arrowhead Pharmaceuticals Is Flying Higher on the Charts
Before I give my recommendation I want to visit with the charts and indicators.
For Boeing and Johnson & Johnson: Where There's Smoke, There's Fire
Both BA and JNJ appear to have made decisions in which the bottom line took precedent over what they stand for as a company.
Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter
I have the answer behind the conundrum that forces stocks up that should be going lower.
Jim Cramer: Netflix and CSX Lead the 'NABAF' Earnings Story
These stocks's earnings were 'not as bad as feared,' and here are some more names that pushed the NABAF narrative.
Jim Cramer: The Market Is Lapping Up These Stocks
There are plenty of senior growth companies that can still move higher.
Key Market Observations
As mentioned earlier, breadth was only 2-1 positive with UnitedHealth , JPMorgan and Johnson & Johnson responsible for a large portion of the market's gains. Bond yields rose, aiding the rate-sensitive banks (who generally met expectations). FANG ha...
Jim Cramer: Here's What We Can Bask in Today
On days like today you realize how much of this market has been mauled by the bear.
Advancers Over Decliners
"Only" about 2-1 advancers over decliners as UnitedHealth Care , JP Morgan and Johnson & Johnson account for a disproportionate amount of the market's rally.
Valuation and 2 Names to Watch Into Earnings: Market Recon
Citigroup and Lululemon are on the radar this morning.
Fed 'Blindsided' Again, Peloton's No Bargain, Trading Jabil: Market Recon
Does the Fed just keep injecting liquidity into money markets every single night forever?
Jim Cramer: Here's Why the Market's So Feckless and Reactive
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
For Wealth and Safety Invest With a 'Shark'
Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.
These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding
By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.
Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
Johnson & Johnson Is in the News, but How Do the Charts Look?
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
3 Stocks That Would Be Hurt by a Strong Dollar
3M, Caterpillar and Johnson & Johnson all face headwinds with a strong dollar.
Charts of Alcon Look Good
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
